Molecular Oncology · 2011 · 40 citations · 16 references
Life SciencesMolecular BiologyOncologyGene ExpressionSignal TransductionTranscriptional RegulationCancer Cell SignalingCancer ProgressionOncogenic ProliferationOncogenic Signaling PathwaysSignal Transduction In CancerLung Cancer ResectionLung Squamous Cell CarcinomaNon-small Cell Lung Cancer TherapyNon-small Cell Lung Cancer TreatmentPhosphoinositide 3-Kinase SignalingStat3 Signaling
Protein Inhibitor of Activated Signal Transducer and Activators of Transcription 3 (PIAS3) is an endogenous inhibitor of STAT3 transcriptional activity. We have previously demonstrated the concentration-dependent negative regulatory effect of PIAS3 on STAT3 signaling and its capacity to decrease lung cancer proliferation and synergize with epidermal growth factor inhibition. We now investigate PIAS3 expression in both non-small cell lung cancer (NSCLC) cell lines and human resected NSCLC specimens. We also investigated the mechanism by which some lung cancers have significantly decreased PIAS3 expression. Expression of PIAS3 is variable in lung cancer cells lines with 2 of 3 squamous cell carcinoma (SCC) cell lines having no or little PIAS3 protein expression. Similarly, the majority of human SCCs of the lung lack PIAS3 expression by immunohistochemistry; this despite the finding that SCCs have significantly higher levels of PIAS3 mRNA compared to adenocarcinomas. High PIAS3 expression generally correlates with decreased phosphorylated STAT3 in both SCC cell lines and human specimens compatible with the negative regulatory effect of this protein on STAT3 signaling. To investigate this variable expression of PIAS3 we first performed sequencing of the PIAS3 gene that demonstrated single nucleotide polymorphisms but no mutations. Exposure of lung cancer cells to 5-azacytidine and trichostatin A results in a significant increase in PIAS3 mRNA and protein expression. However, methylation-specific PCR demonstrates a lack of CpG island methylation in the promoter region of PIAS3. Exposure of cells to an agent blocking proteosomal degradation results in a significant increase in PIAS3. Our data thus shows that SCC of the lung commonly lacks PIAS3 protein expression and that post-translational modifications may explain this finding in some cases. PIAS3 is a potential therapeutic molecule to target STAT3 pathway in lung cancer.
16
Ahmedin Jemal, Rebecca L. Siegel, Elizabeth Ward et al. · CA A Cancer Journal for Clinicians · 2009 · 9.7K citations · Full text
A family of cytokine-inducible inhibitors of signalling
Robyn Starr, Tracy A. Willson, Elizabeth M. Viney et al. · Nature · 1997 · 2.1K citations
A new protein containing an SH2 domain that inhibits JAK kinases
Takaho A. Endo, Masaaki Masuhara, Masahiro Yokouchi et al. · Nature · 1997 · 1.4K citations
Structure and function of a new STAT-induced STAT inhibitor
Tetsuji Naka, Masashi Narazaki, Moritoshi Hirata et al. · Nature · 1997 · 1.3K citations · Full text